Walk Through Survey Report. Exposure to Diethylstilbestrol at Eli Lilly and Company, Indianapolis, Indiana, Report No. IWS-085-21.
NIOSH 1980 Mar:22 pages
This walk through survey was conducted at Eli Lilly and Company, Indianapolis, Indiana, to investigate potential exposure to estrogenic substances at a facility engaged in manufacturing pharmaceuticals. About 4,200 workers were directly involved in the production of pharmaceuticals, but only about 70 were involved with diethylstilbestrol (56531) (DES). This facility was engaged in the synthesis of diethylstilbestrol from the 1940s through 1972; DES containing tablets and suppositories have been produced and packaged at the facility intermittently since 1972. Manufacturing and packaging operations and the medical program at the facility were described. Due to the relatively open processing methods and the frequent need for material transfers in the DES product manufacturing processes, there was a potential for intermittent exposure to DES at this facility. Current exposures and the degree of environmental variation at this location have not been adequately measured. Medical data for the site indicate that there have been no cases of hyperestrogenism since 1972. The authors conclude that an in depth industrial hygiene survey should be performed at this facility. Medical studies should also be performed at the same time.
NIOSH-Author; NIOSH-Survey; Field-Study; IWS-085-21; Region-5; Pharmaceutical-industry; Inhalants; Skin-exposure; Estrogenic-hormones;
NTIS Accession No.
Division of Surveillance, Hazard Evaluations and Field Studies, NIOSH, U.S. Department of Health, Education, and Welfare, Cincinnati, Ohio, 22 pages